Myelodysplastic syndromes ( MDS ) is a heterogeneous collection of hematopoietic stem cell disorders that result in cytopenias and risk of progression to acute myeloid leukemia ( AML ). Management of anemia through erythropoiesis-stimulating agents or more aggressive treatment with hypomethylating agents has long been the standard of care for lower- and higher-risk MDS patients, respectively. Development of therapies for patients who become refractory to standard-of-care treatments is the key unmet need for this market. The MDS pipeline is robust, and several projected market entrants are poised to penetrate subpopulations of the lower-risk MDS market. While development of novel agents for higher-risk MDS patients is active, this segment of the market has proved to be challenging for developers to demonstrate overall survival benefit.\u00a0
\nQuestions Answered:\u00a0<\/p>\n
\nScope\u00a0<\/strong><\/p>\n Markets covered : United States, France, Germany, Italy, Spain, and the United Kingdom.\u00a0 How do interviewed experts perceive currently available MDS therapies?\u00a0 Myelodysplastic syndromes ( MDS ) is a heterogeneous collection of hematopoietic stem cell disorders that result in cytopenias and risk of progression to acute myeloid leukemia ( AML ). Management of anemia through erythropoiesis-stimulating agents or more aggressive treatment with hypomethylating agents has long been the standard of care for lower- and higher-risk MDS patients, respectively. Development of therapies for patients who become refractory to standard-of-care treatments is the key unmet need for this market. The MDS pipeline is robust, and several projected market entrants are poised to penetrate subpopulations of the lower-risk MDS market. While development of novel agents for higher-risk MDS patients is active, this segment of the market has proved to be challenging for developers to demonstrate overall survival benefit.<\/p>\n \nMarkets covered :<\/strong>\u00a0United States, France, Germany, Italy, Spain, and the United Kingdom.\u00a0
\nPrimary research : Six country-specific interviews with thought leading hematologists.\u00a0
\nEpidemiology : Incident and diagnosed prevalent cases of MDS by country, morphology, and prognostic risk; including drug-treated cases.\u00a0
\nMarket forecast : Drug-level sales and patient share of key MDS therapies in 2026.\u00a0
\nEmerging therapies : Phase III: 7 drugs. Phase II: 21 drugs. Coverage of select Phase I\/II and I products.\u00a0
\nKey companies : Celgene, Otsuka, Amgen, Janssen,\u00a0Acceleron, Novartis, Agios, Jazz, Celator, Onconova, Astex.\u00a0
\nKey drugs : Azacitidine (Vidaza, generics), decitabine (Dacogen, generics),\u00a0Revlimid (lenalidomide), epoetin alfa (Epogen, Procrit), darbepoetin alfa (Aranesp), CC -486, luspatercept, eltrombopag (Promacta\/Revolade), enasidenib, CPX-351 (Vyxeos), rigosertib (Estybon), guadecitabine.\u00a0<\/p>\nQuestions Answered in This Report:<\/h3>\n
\n
\n\tWill further research into genetic markers impact either diagnosis or prognosis in MDS ?\u00a0
\n\tWhat emerging therapies are most likely to impact the MDS market in 2026?\u00a0\u00a0
\n\tHow will Celgene\u2019s oral azacitidine ( CC -486) be received by physicians? What will be the off-label use if the label is restricted to lower-risk patients?\u00a0
\n\tWill Celgene\u2019s luspatercept ( ACE -536) be limited to a second-line option for lower-risk MDS patients?\u00a0
\n\tWhat therapies currently marketed or are in late-phase development for AML will have relevance in the MDS market?\u00a0<\/p>\n<\/li>\n<\/ul>\nScope:<\/h3>\n
\nPrimary research : Six country-specific interviews with thought leading hematologists.\u00a0
\nEpidemiology : Incident and diagnosed prevalent cases of MDS by country, morphology, and prognostic risk; including drug-treated cases.\u00a0
\nMarket forecast : Drug-level sales and patient share of key MDS therapies in 2026.\u00a0
\nEmerging therapies : Phase III: 7 drugs. Phase II: 21 drugs. Coverage of select Phase I\/II and I products.\u00a0
\nKey companies : Celgene, Otsuka, Amgen, Janssen,\u00a0Acceleron, Novartis, Agios, Jazz, Celator, Onconova, Astex.\u00a0
\nKey drugs : Azacitidine (Vidaza, generics), decitabine (Dacogen, generics),\u00a0Revlimid (lenalidomide), epoetin alfa (Epogen, Procrit), darbepoetin alfa (Aranesp), CC -486, luspatercept, eltrombopag (Promacta\/Revolade), enasidenib, CPX-351 (Vyxeos), rigosertib (Estybon), guadecitabine.\u00a0<\/p>\n","protected":false},"template":"","class_list":["post-390727","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-myelodysplastic-syndromes","biopharma-geography-us","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390727","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390727\/revisions"}],"predecessor-version":[{"id":576750,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390727\/revisions\/576750"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390727"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}